Global Human Genetically Engineered Vaccine Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Human Genetically Engineered Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Human Genetically Engineered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Human Genetically Engineered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Human Genetically Engineered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Human Genetically Engineered Vaccine players cover Pfizer, Merck, GSK, Beijing Wantai Biological Pharmacy Enterprise CO.,LTD., Walvax Biotechnology Co., Ltd., Bharat Biotech, Chengdu Kanghua Biological Products Co., Ltd., South China Vaccine Corporation Limited and Beijing Health Guard Biotechnology Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Human Genetically Engineered Vaccine Industry Forecast” looks at past sales and reviews total world Human Genetically Engineered Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Genetically Engineered Vaccine sales for 2023 through 2029. With Human Genetically Engineered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Genetically Engineered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Genetically Engineered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Genetically Engineered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Genetically Engineered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Genetically Engineered Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Genetically Engineered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Genetically Engineered Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Human Genetically Engineered Vaccine market?
What factors are driving Human Genetically Engineered Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Genetically Engineered Vaccine market opportunities vary by end market size?
How does Human Genetically Engineered Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The global Human Genetically Engineered Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Human Genetically Engineered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Human Genetically Engineered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Human Genetically Engineered Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Human Genetically Engineered Vaccine players cover Pfizer, Merck, GSK, Beijing Wantai Biological Pharmacy Enterprise CO.,LTD., Walvax Biotechnology Co., Ltd., Bharat Biotech, Chengdu Kanghua Biological Products Co., Ltd., South China Vaccine Corporation Limited and Beijing Health Guard Biotechnology Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Human Genetically Engineered Vaccine Industry Forecast” looks at past sales and reviews total world Human Genetically Engineered Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Genetically Engineered Vaccine sales for 2023 through 2029. With Human Genetically Engineered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Genetically Engineered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Human Genetically Engineered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Genetically Engineered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Genetically Engineered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Genetically Engineered Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Genetically Engineered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Genetically Engineered Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Genetic Recombinant Vaccine
- Recombinant Subunit Vaccines
- Genetic Vaccine
- Hepatitis E
- Human Papillomavirus (HPV)
- Rotavirus
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Merck
- GSK
- Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
- Walvax Biotechnology Co., Ltd.
- Bharat Biotech
- Chengdu Kanghua Biological Products Co., Ltd.
- South China Vaccine Corporation Limited
- Beijing Health Guard Biotechnology Inc.
- CSL Limited
- Emergent BioSolutions
- Sanofi Pasteur
- Serum Institute
What is the 10-year outlook for the global Human Genetically Engineered Vaccine market?
What factors are driving Human Genetically Engineered Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Genetically Engineered Vaccine market opportunities vary by end market size?
How does Human Genetically Engineered Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Genetically Engineered Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Genetically Engineered Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Genetically Engineered Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Human Genetically Engineered Vaccine Segment by Type
2.2.1 Genetic Recombinant Vaccine
2.2.2 Recombinant Subunit Vaccines
2.2.3 Genetic Vaccine
2.3 Human Genetically Engineered Vaccine Sales by Type
2.3.1 Global Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Genetically Engineered Vaccine Sale Price by Type (2018-2023)
2.4 Human Genetically Engineered Vaccine Segment by Application
2.4.1 Hepatitis E
2.4.2 Human Papillomavirus (HPV)
2.4.3 Rotavirus
2.4.4 Others
2.5 Human Genetically Engineered Vaccine Sales by Application
2.5.1 Global Human Genetically Engineered Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Genetically Engineered Vaccine Sale Price by Application (2018-2023)
3 GLOBAL HUMAN GENETICALLY ENGINEERED VACCINE BY COMPANY
3.1 Global Human Genetically Engineered Vaccine Breakdown Data by Company
3.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Human Genetically Engineered Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Human Genetically Engineered Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Human Genetically Engineered Vaccine Revenue by Company (2018-2023)
3.2.2 Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Human Genetically Engineered Vaccine Sale Price by Company
3.4 Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Genetically Engineered Vaccine Product Location Distribution
3.4.2 Players Human Genetically Engineered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Human Genetically Engineered Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Genetically Engineered Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Genetically Engineered Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Human Genetically Engineered Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Genetically Engineered Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Genetically Engineered Vaccine Sales Growth
4.4 APAC Human Genetically Engineered Vaccine Sales Growth
4.5 Europe Human Genetically Engineered Vaccine Sales Growth
4.6 Middle East & Africa Human Genetically Engineered Vaccine Sales Growth
5 AMERICAS
5.1 Americas Human Genetically Engineered Vaccine Sales by Country
5.1.1 Americas Human Genetically Engineered Vaccine Sales by Country (2018-2023)
5.1.2 Americas Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
5.2 Americas Human Genetically Engineered Vaccine Sales by Type
5.3 Americas Human Genetically Engineered Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Genetically Engineered Vaccine Sales by Region
6.1.1 APAC Human Genetically Engineered Vaccine Sales by Region (2018-2023)
6.1.2 APAC Human Genetically Engineered Vaccine Revenue by Region (2018-2023)
6.2 APAC Human Genetically Engineered Vaccine Sales by Type
6.3 APAC Human Genetically Engineered Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Genetically Engineered Vaccine by Country
7.1.1 Europe Human Genetically Engineered Vaccine Sales by Country (2018-2023)
7.1.2 Europe Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
7.2 Europe Human Genetically Engineered Vaccine Sales by Type
7.3 Europe Human Genetically Engineered Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Genetically Engineered Vaccine by Country
8.1.1 Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Genetically Engineered Vaccine Sales by Type
8.3 Middle East & Africa Human Genetically Engineered Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine
10.3 Manufacturing Process Analysis of Human Genetically Engineered Vaccine
10.4 Industry Chain Structure of Human Genetically Engineered Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Genetically Engineered Vaccine Distributors
11.3 Human Genetically Engineered Vaccine Customer
12 WORLD FORECAST REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
12.1 Global Human Genetically Engineered Vaccine Market Size Forecast by Region
12.1.1 Global Human Genetically Engineered Vaccine Forecast by Region (2024-2029)
12.1.2 Global Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Genetically Engineered Vaccine Forecast by Type
12.7 Global Human Genetically Engineered Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
13.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
13.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business Overview
13.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
13.5 Walvax Biotechnology Co., Ltd.
13.5.1 Walvax Biotechnology Co., Ltd. Company Information
13.5.2 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Walvax Biotechnology Co., Ltd. Main Business Overview
13.5.5 Walvax Biotechnology Co., Ltd. Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Chengdu Kanghua Biological Products Co., Ltd.
13.7.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.7.2 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.7.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.7.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.8 South China Vaccine Corporation Limited
13.8.1 South China Vaccine Corporation Limited Company Information
13.8.2 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 South China Vaccine Corporation Limited Main Business Overview
13.8.5 South China Vaccine Corporation Limited Latest Developments
13.9 Beijing Health Guard Biotechnology Inc.
13.9.1 Beijing Health Guard Biotechnology Inc. Company Information
13.9.2 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Beijing Health Guard Biotechnology Inc. Main Business Overview
13.9.5 Beijing Health Guard Biotechnology Inc. Latest Developments
13.10 CSL Limited
13.10.1 CSL Limited Company Information
13.10.2 CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 CSL Limited Main Business Overview
13.10.5 CSL Limited Latest Developments
13.11 Emergent BioSolutions
13.11.1 Emergent BioSolutions Company Information
13.11.2 Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Emergent BioSolutions Main Business Overview
13.11.5 Emergent BioSolutions Latest Developments
13.12 Sanofi Pasteur
13.12.1 Sanofi Pasteur Company Information
13.12.2 Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sanofi Pasteur Main Business Overview
13.12.5 Sanofi Pasteur Latest Developments
13.13 Serum Institute
13.13.1 Serum Institute Company Information
13.13.2 Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Serum Institute Main Business Overview
13.13.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Human Genetically Engineered Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Genetically Engineered Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Genetically Engineered Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Human Genetically Engineered Vaccine Segment by Type
2.2.1 Genetic Recombinant Vaccine
2.2.2 Recombinant Subunit Vaccines
2.2.3 Genetic Vaccine
2.3 Human Genetically Engineered Vaccine Sales by Type
2.3.1 Global Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Genetically Engineered Vaccine Sale Price by Type (2018-2023)
2.4 Human Genetically Engineered Vaccine Segment by Application
2.4.1 Hepatitis E
2.4.2 Human Papillomavirus (HPV)
2.4.3 Rotavirus
2.4.4 Others
2.5 Human Genetically Engineered Vaccine Sales by Application
2.5.1 Global Human Genetically Engineered Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Human Genetically Engineered Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Genetically Engineered Vaccine Sale Price by Application (2018-2023)
3 GLOBAL HUMAN GENETICALLY ENGINEERED VACCINE BY COMPANY
3.1 Global Human Genetically Engineered Vaccine Breakdown Data by Company
3.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Human Genetically Engineered Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Human Genetically Engineered Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Human Genetically Engineered Vaccine Revenue by Company (2018-2023)
3.2.2 Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Human Genetically Engineered Vaccine Sale Price by Company
3.4 Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Genetically Engineered Vaccine Product Location Distribution
3.4.2 Players Human Genetically Engineered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Human Genetically Engineered Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Genetically Engineered Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Genetically Engineered Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Genetically Engineered Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Human Genetically Engineered Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Genetically Engineered Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Genetically Engineered Vaccine Sales Growth
4.4 APAC Human Genetically Engineered Vaccine Sales Growth
4.5 Europe Human Genetically Engineered Vaccine Sales Growth
4.6 Middle East & Africa Human Genetically Engineered Vaccine Sales Growth
5 AMERICAS
5.1 Americas Human Genetically Engineered Vaccine Sales by Country
5.1.1 Americas Human Genetically Engineered Vaccine Sales by Country (2018-2023)
5.1.2 Americas Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
5.2 Americas Human Genetically Engineered Vaccine Sales by Type
5.3 Americas Human Genetically Engineered Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Genetically Engineered Vaccine Sales by Region
6.1.1 APAC Human Genetically Engineered Vaccine Sales by Region (2018-2023)
6.1.2 APAC Human Genetically Engineered Vaccine Revenue by Region (2018-2023)
6.2 APAC Human Genetically Engineered Vaccine Sales by Type
6.3 APAC Human Genetically Engineered Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Human Genetically Engineered Vaccine by Country
7.1.1 Europe Human Genetically Engineered Vaccine Sales by Country (2018-2023)
7.1.2 Europe Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
7.2 Europe Human Genetically Engineered Vaccine Sales by Type
7.3 Europe Human Genetically Engineered Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Human Genetically Engineered Vaccine by Country
8.1.1 Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Genetically Engineered Vaccine Sales by Type
8.3 Middle East & Africa Human Genetically Engineered Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine
10.3 Manufacturing Process Analysis of Human Genetically Engineered Vaccine
10.4 Industry Chain Structure of Human Genetically Engineered Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Genetically Engineered Vaccine Distributors
11.3 Human Genetically Engineered Vaccine Customer
12 WORLD FORECAST REVIEW FOR HUMAN GENETICALLY ENGINEERED VACCINE BY GEOGRAPHIC REGION
12.1 Global Human Genetically Engineered Vaccine Market Size Forecast by Region
12.1.1 Global Human Genetically Engineered Vaccine Forecast by Region (2024-2029)
12.1.2 Global Human Genetically Engineered Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Genetically Engineered Vaccine Forecast by Type
12.7 Global Human Genetically Engineered Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 GSK
13.3.1 GSK Company Information
13.3.2 GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GSK Main Business Overview
13.3.5 GSK Latest Developments
13.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
13.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Company Information
13.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business Overview
13.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
13.5 Walvax Biotechnology Co., Ltd.
13.5.1 Walvax Biotechnology Co., Ltd. Company Information
13.5.2 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Walvax Biotechnology Co., Ltd. Main Business Overview
13.5.5 Walvax Biotechnology Co., Ltd. Latest Developments
13.6 Bharat Biotech
13.6.1 Bharat Biotech Company Information
13.6.2 Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Bharat Biotech Main Business Overview
13.6.5 Bharat Biotech Latest Developments
13.7 Chengdu Kanghua Biological Products Co., Ltd.
13.7.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
13.7.2 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.7.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Chengdu Kanghua Biological Products Co., Ltd. Main Business Overview
13.7.5 Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
13.8 South China Vaccine Corporation Limited
13.8.1 South China Vaccine Corporation Limited Company Information
13.8.2 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 South China Vaccine Corporation Limited Main Business Overview
13.8.5 South China Vaccine Corporation Limited Latest Developments
13.9 Beijing Health Guard Biotechnology Inc.
13.9.1 Beijing Health Guard Biotechnology Inc. Company Information
13.9.2 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Beijing Health Guard Biotechnology Inc. Main Business Overview
13.9.5 Beijing Health Guard Biotechnology Inc. Latest Developments
13.10 CSL Limited
13.10.1 CSL Limited Company Information
13.10.2 CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 CSL Limited Main Business Overview
13.10.5 CSL Limited Latest Developments
13.11 Emergent BioSolutions
13.11.1 Emergent BioSolutions Company Information
13.11.2 Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Emergent BioSolutions Main Business Overview
13.11.5 Emergent BioSolutions Latest Developments
13.12 Sanofi Pasteur
13.12.1 Sanofi Pasteur Company Information
13.12.2 Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sanofi Pasteur Main Business Overview
13.12.5 Sanofi Pasteur Latest Developments
13.13 Serum Institute
13.13.1 Serum Institute Company Information
13.13.2 Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
13.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Serum Institute Main Business Overview
13.13.5 Serum Institute Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Human Genetically Engineered Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Human Genetically Engineered Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Genetic Recombinant Vaccine
Table 4. Major Players of Recombinant Subunit Vaccines
Table 5. Major Players of Genetic Vaccine
Table 6. Global Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 7. Global Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Table 8. Global Human Genetically Engineered Vaccine Revenue by Type (2018-2023) & ($ million)
Table 9. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2018-2023)
Table 10. Global Human Genetically Engineered Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 12. Global Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Table 13. Global Human Genetically Engineered Vaccine Revenue by Application (2018-2023)
Table 14. Global Human Genetically Engineered Vaccine Revenue Market Share by Application (2018-2023)
Table 15. Global Human Genetically Engineered Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Human Genetically Engineered Vaccine Sales by Company (2018-2023) & (K Units)
Table 17. Global Human Genetically Engineered Vaccine Sales Market Share by Company (2018-2023)
Table 18. Global Human Genetically Engineered Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2018-2023)
Table 20. Global Human Genetically Engineered Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution and Sales Area
Table 22. Players Human Genetically Engineered Vaccine Products Offered
Table 23. Human Genetically Engineered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Human Genetically Engineered Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Human Genetically Engineered Vaccine Sales Market Share Geographic Region (2018-2023)
Table 28. Global Human Genetically Engineered Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Human Genetically Engineered Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2018-2023)
Table 32. Global Human Genetically Engineered Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Human Genetically Engineered Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Human Genetically Engineered Vaccine Sales by Country (2018-2023) & (K Units)
Table 35. Americas Human Genetically Engineered Vaccine Sales Market Share by Country (2018-2023)
Table 36. Americas Human Genetically Engineered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Human Genetically Engineered Vaccine Revenue Market Share by Country (2018-2023)
Table 38. Americas Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 39. Americas Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 40. APAC Human Genetically Engineered Vaccine Sales by Region (2018-2023) & (K Units)
Table 41. APAC Human Genetically Engineered Vaccine Sales Market Share by Region (2018-2023)
Table 42. APAC Human Genetically Engineered Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Human Genetically Engineered Vaccine Revenue Market Share by Region (2018-2023)
Table 44. APAC Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 45. APAC Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 46. Europe Human Genetically Engineered Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Europe Human Genetically Engineered Vaccine Sales Market Share by Country (2018-2023)
Table 48. Europe Human Genetically Engineered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Human Genetically Engineered Vaccine Revenue Market Share by Country (2018-2023)
Table 50. Europe Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 51. Europe Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Human Genetically Engineered Vaccine Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Human Genetically Engineered Vaccine
Table 59. Key Market Challenges & Risks of Human Genetically Engineered Vaccine
Table 60. Key Industry Trends of Human Genetically Engineered Vaccine
Table 61. Human Genetically Engineered Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Human Genetically Engineered Vaccine Distributors List
Table 64. Human Genetically Engineered Vaccine Customer List
Table 65. Global Human Genetically Engineered Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Human Genetically Engineered Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Human Genetically Engineered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Human Genetically Engineered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Human Genetically Engineered Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Human Genetically Engineered Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Human Genetically Engineered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Human Genetically Engineered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Human Genetically Engineered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Human Genetically Engineered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Human Genetically Engineered Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Human Genetically Engineered Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Human Genetically Engineered Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Human Genetically Engineered Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Pfizer Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 81. Pfizer Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Merck Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 86. Merck Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Merck Main Business
Table 88. Merck Latest Developments
Table 89. GSK Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 91. GSK Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. GSK Main Business
Table 93. GSK Latest Developments
Table 94. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 96. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business
Table 98. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
Table 99. Walvax Biotechnology Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 101. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Walvax Biotechnology Co., Ltd. Main Business
Table 103. Walvax Biotechnology Co., Ltd. Latest Developments
Table 104. Bharat Biotech Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 106. Bharat Biotech Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Bharat Biotech Main Business
Table 108. Bharat Biotech Latest Developments
Table 109. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 111. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 113. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
Table 114. South China Vaccine Corporation Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 116. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. South China Vaccine Corporation Limited Main Business
Table 118. South China Vaccine Corporation Limited Latest Developments
Table 119. Beijing Health Guard Biotechnology Inc. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 121. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Beijing Health Guard Biotechnology Inc. Main Business
Table 123. Beijing Health Guard Biotechnology Inc. Latest Developments
Table 124. CSL Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 126. CSL Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. CSL Limited Main Business
Table 128. CSL Limited Latest Developments
Table 129. Emergent BioSolutions Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 131. Emergent BioSolutions Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Emergent BioSolutions Main Business
Table 133. Emergent BioSolutions Latest Developments
Table 134. Sanofi Pasteur Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 136. Sanofi Pasteur Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Sanofi Pasteur Main Business
Table 138. Sanofi Pasteur Latest Developments
Table 139. Serum Institute Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 141. Serum Institute Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Serum Institute Main Business
Table 143. Serum Institute Latest Developments
Table 1. Human Genetically Engineered Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Human Genetically Engineered Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Genetic Recombinant Vaccine
Table 4. Major Players of Recombinant Subunit Vaccines
Table 5. Major Players of Genetic Vaccine
Table 6. Global Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 7. Global Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Table 8. Global Human Genetically Engineered Vaccine Revenue by Type (2018-2023) & ($ million)
Table 9. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2018-2023)
Table 10. Global Human Genetically Engineered Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 12. Global Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Table 13. Global Human Genetically Engineered Vaccine Revenue by Application (2018-2023)
Table 14. Global Human Genetically Engineered Vaccine Revenue Market Share by Application (2018-2023)
Table 15. Global Human Genetically Engineered Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Human Genetically Engineered Vaccine Sales by Company (2018-2023) & (K Units)
Table 17. Global Human Genetically Engineered Vaccine Sales Market Share by Company (2018-2023)
Table 18. Global Human Genetically Engineered Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Human Genetically Engineered Vaccine Revenue Market Share by Company (2018-2023)
Table 20. Global Human Genetically Engineered Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Human Genetically Engineered Vaccine Producing Area Distribution and Sales Area
Table 22. Players Human Genetically Engineered Vaccine Products Offered
Table 23. Human Genetically Engineered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Human Genetically Engineered Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Human Genetically Engineered Vaccine Sales Market Share Geographic Region (2018-2023)
Table 28. Global Human Genetically Engineered Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Human Genetically Engineered Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Human Genetically Engineered Vaccine Sales Market Share by Country/Region (2018-2023)
Table 32. Global Human Genetically Engineered Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Human Genetically Engineered Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Human Genetically Engineered Vaccine Sales by Country (2018-2023) & (K Units)
Table 35. Americas Human Genetically Engineered Vaccine Sales Market Share by Country (2018-2023)
Table 36. Americas Human Genetically Engineered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Human Genetically Engineered Vaccine Revenue Market Share by Country (2018-2023)
Table 38. Americas Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 39. Americas Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 40. APAC Human Genetically Engineered Vaccine Sales by Region (2018-2023) & (K Units)
Table 41. APAC Human Genetically Engineered Vaccine Sales Market Share by Region (2018-2023)
Table 42. APAC Human Genetically Engineered Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Human Genetically Engineered Vaccine Revenue Market Share by Region (2018-2023)
Table 44. APAC Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 45. APAC Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 46. Europe Human Genetically Engineered Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Europe Human Genetically Engineered Vaccine Sales Market Share by Country (2018-2023)
Table 48. Europe Human Genetically Engineered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Human Genetically Engineered Vaccine Revenue Market Share by Country (2018-2023)
Table 50. Europe Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 51. Europe Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Human Genetically Engineered Vaccine Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Human Genetically Engineered Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Human Genetically Engineered Vaccine Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Human Genetically Engineered Vaccine Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Human Genetically Engineered Vaccine Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Human Genetically Engineered Vaccine
Table 59. Key Market Challenges & Risks of Human Genetically Engineered Vaccine
Table 60. Key Industry Trends of Human Genetically Engineered Vaccine
Table 61. Human Genetically Engineered Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Human Genetically Engineered Vaccine Distributors List
Table 64. Human Genetically Engineered Vaccine Customer List
Table 65. Global Human Genetically Engineered Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Human Genetically Engineered Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Human Genetically Engineered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Human Genetically Engineered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Human Genetically Engineered Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Human Genetically Engineered Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Human Genetically Engineered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Human Genetically Engineered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Human Genetically Engineered Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Human Genetically Engineered Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Human Genetically Engineered Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Human Genetically Engineered Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Human Genetically Engineered Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Human Genetically Engineered Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Pfizer Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 81. Pfizer Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Merck Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Merck Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 86. Merck Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Merck Main Business
Table 88. Merck Latest Developments
Table 89. GSK Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. GSK Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 91. GSK Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. GSK Main Business
Table 93. GSK Latest Developments
Table 94. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 96. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Main Business
Table 98. Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Latest Developments
Table 99. Walvax Biotechnology Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 101. Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Walvax Biotechnology Co., Ltd. Main Business
Table 103. Walvax Biotechnology Co., Ltd. Latest Developments
Table 104. Bharat Biotech Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Bharat Biotech Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 106. Bharat Biotech Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Bharat Biotech Main Business
Table 108. Bharat Biotech Latest Developments
Table 109. Chengdu Kanghua Biological Products Co., Ltd. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 111. Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Chengdu Kanghua Biological Products Co., Ltd. Main Business
Table 113. Chengdu Kanghua Biological Products Co., Ltd. Latest Developments
Table 114. South China Vaccine Corporation Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 116. South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. South China Vaccine Corporation Limited Main Business
Table 118. South China Vaccine Corporation Limited Latest Developments
Table 119. Beijing Health Guard Biotechnology Inc. Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 121. Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Beijing Health Guard Biotechnology Inc. Main Business
Table 123. Beijing Health Guard Biotechnology Inc. Latest Developments
Table 124. CSL Limited Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. CSL Limited Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 126. CSL Limited Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. CSL Limited Main Business
Table 128. CSL Limited Latest Developments
Table 129. Emergent BioSolutions Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 131. Emergent BioSolutions Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Emergent BioSolutions Main Business
Table 133. Emergent BioSolutions Latest Developments
Table 134. Sanofi Pasteur Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 136. Sanofi Pasteur Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Sanofi Pasteur Main Business
Table 138. Sanofi Pasteur Latest Developments
Table 139. Serum Institute Basic Information, Human Genetically Engineered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Serum Institute Human Genetically Engineered Vaccine Product Portfolios and Specifications
Table 141. Serum Institute Human Genetically Engineered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Serum Institute Main Business
Table 143. Serum Institute Latest Developments
LIST OF FIGURES
Figure 1. Picture of Human Genetically Engineered Vaccine
Figure 2. Human Genetically Engineered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Genetically Engineered Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Human Genetically Engineered Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Human Genetically Engineered Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Genetic Recombinant Vaccine
Figure 10. Product Picture of Recombinant Subunit Vaccines
Figure 11. Product Picture of Genetic Vaccine
Figure 12. Global Human Genetically Engineered Vaccine Sales Market Share by Type in 2022
Figure 13. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2018-2023)
Figure 14. Human Genetically Engineered Vaccine Consumed in Hepatitis E
Figure 15. Global Human Genetically Engineered Vaccine Market: Hepatitis E (2018-2023) & (K Units)
Figure 16. Human Genetically Engineered Vaccine Consumed in Human Papillomavirus (HPV)
Figure 17. Global Human Genetically Engineered Vaccine Market: Human Papillomavirus (HPV) (2018-2023) & (K Units)
Figure 18. Human Genetically Engineered Vaccine Consumed in Rotavirus
Figure 19. Global Human Genetically Engineered Vaccine Market: Rotavirus (2018-2023) & (K Units)
Figure 20. Human Genetically Engineered Vaccine Consumed in Others
Figure 21. Global Human Genetically Engineered Vaccine Market: Others (2018-2023) & (K Units)
Figure 22. Global Human Genetically Engineered Vaccine Sales Market Share by Application (2022)
Figure 23. Global Human Genetically Engineered Vaccine Revenue Market Share by Application in 2022
Figure 24. Human Genetically Engineered Vaccine Sales Market by Company in 2022 (K Units)
Figure 25. Global Human Genetically Engineered Vaccine Sales Market Share by Company in 2022
Figure 26. Human Genetically Engineered Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Human Genetically Engineered Vaccine Revenue Market Share by Company in 2022
Figure 28. Global Human Genetically Engineered Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 31. Americas Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 32. APAC Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 33. APAC Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 34. Europe Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 35. Europe Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 38. Americas Human Genetically Engineered Vaccine Sales Market Share by Country in 2022
Figure 39. Americas Human Genetically Engineered Vaccine Revenue Market Share by Country in 2022
Figure 40. Americas Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 41. Americas Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 42. United States Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Human Genetically Engineered Vaccine Sales Market Share by Region in 2022
Figure 47. APAC Human Genetically Engineered Vaccine Revenue Market Share by Regions in 2022
Figure 48. APAC Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 49. APAC Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 50. China Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Human Genetically Engineered Vaccine Sales Market Share by Country in 2022
Figure 58. Europe Human Genetically Engineered Vaccine Revenue Market Share by Country in 2022
Figure 59. Europe Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 60. Europe Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 61. Germany Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Human Genetically Engineered Vaccine Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 70. Egypt Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine in 2022
Figure 76. Manufacturing Process Analysis of Human Genetically Engineered Vaccine
Figure 77. Industry Chain Structure of Human Genetically Engineered Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Human Genetically Engineered Vaccine Sales Market Forecast by Region (2024-2029)
Figure 80. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Human Genetically Engineered Vaccine
Figure 2. Human Genetically Engineered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Genetically Engineered Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Human Genetically Engineered Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Human Genetically Engineered Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Genetic Recombinant Vaccine
Figure 10. Product Picture of Recombinant Subunit Vaccines
Figure 11. Product Picture of Genetic Vaccine
Figure 12. Global Human Genetically Engineered Vaccine Sales Market Share by Type in 2022
Figure 13. Global Human Genetically Engineered Vaccine Revenue Market Share by Type (2018-2023)
Figure 14. Human Genetically Engineered Vaccine Consumed in Hepatitis E
Figure 15. Global Human Genetically Engineered Vaccine Market: Hepatitis E (2018-2023) & (K Units)
Figure 16. Human Genetically Engineered Vaccine Consumed in Human Papillomavirus (HPV)
Figure 17. Global Human Genetically Engineered Vaccine Market: Human Papillomavirus (HPV) (2018-2023) & (K Units)
Figure 18. Human Genetically Engineered Vaccine Consumed in Rotavirus
Figure 19. Global Human Genetically Engineered Vaccine Market: Rotavirus (2018-2023) & (K Units)
Figure 20. Human Genetically Engineered Vaccine Consumed in Others
Figure 21. Global Human Genetically Engineered Vaccine Market: Others (2018-2023) & (K Units)
Figure 22. Global Human Genetically Engineered Vaccine Sales Market Share by Application (2022)
Figure 23. Global Human Genetically Engineered Vaccine Revenue Market Share by Application in 2022
Figure 24. Human Genetically Engineered Vaccine Sales Market by Company in 2022 (K Units)
Figure 25. Global Human Genetically Engineered Vaccine Sales Market Share by Company in 2022
Figure 26. Human Genetically Engineered Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Human Genetically Engineered Vaccine Revenue Market Share by Company in 2022
Figure 28. Global Human Genetically Engineered Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Human Genetically Engineered Vaccine Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 31. Americas Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 32. APAC Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 33. APAC Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 34. Europe Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 35. Europe Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Human Genetically Engineered Vaccine Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Human Genetically Engineered Vaccine Revenue 2018-2023 ($ Millions)
Figure 38. Americas Human Genetically Engineered Vaccine Sales Market Share by Country in 2022
Figure 39. Americas Human Genetically Engineered Vaccine Revenue Market Share by Country in 2022
Figure 40. Americas Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 41. Americas Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 42. United States Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Human Genetically Engineered Vaccine Sales Market Share by Region in 2022
Figure 47. APAC Human Genetically Engineered Vaccine Revenue Market Share by Regions in 2022
Figure 48. APAC Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 49. APAC Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 50. China Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Human Genetically Engineered Vaccine Sales Market Share by Country in 2022
Figure 58. Europe Human Genetically Engineered Vaccine Revenue Market Share by Country in 2022
Figure 59. Europe Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 60. Europe Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 61. Germany Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Human Genetically Engineered Vaccine Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Human Genetically Engineered Vaccine Sales Market Share by Application (2018-2023)
Figure 70. Egypt Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Human Genetically Engineered Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Human Genetically Engineered Vaccine in 2022
Figure 76. Manufacturing Process Analysis of Human Genetically Engineered Vaccine
Figure 77. Industry Chain Structure of Human Genetically Engineered Vaccine
Figure 78. Channels of Distribution
Figure 79. Global Human Genetically Engineered Vaccine Sales Market Forecast by Region (2024-2029)
Figure 80. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Human Genetically Engineered Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Human Genetically Engineered Vaccine Revenue Market Share Forecast by Application (2024-2029)
